Zelluna ASA (OSL:ZLNA)
Norway · Delayed Price · Currency is NOK | Market Cap | 567.43M +96.9% |
| Revenue (ttm) | 8.00K -84.9% |
| Net Income | -132.73M |
| EPS | -5.42 |
| Shares Out | 26.27M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,235 |
| Open | 21.70 |
| Previous Close | 21.10 |
| Day's Range | 20.00 - 21.70 |
| 52-Week Range | 8.20 - 35.80 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | May 7, 2026 |
About Zelluna ASA
Zelluna ASA, a clinical-stage biotechnology company, engages in the development of T-cell receptor guided natural killer cell therapies in Norway. It develops ZI-MA4-1 which is in Phase I clinical trial for the treatment of non-small cell lung cancer, ovarian, and head and neck synovial sarcoma; ZI-KL1-1 which is in preclinical trial for the treatment of breast, gastric, lung, pancreatic, and cervix cancers; and ZI-PR-1 which is in discovery stage for the treatment of solid tumors. The company was incorporated in 2016 and is headquartered in Os... [Read more]
Financial Performance
Financial StatementsNews
Zelluna ASA Earnings Call Transcript: Q1 2026
First clinical site activated for TCR-NK cell therapy trial in solid tumors, with initial human data expected mid-2026. Cash position of NOK 50 million supports runway into Q1 2027, and pipeline expansion continues with AI-driven programs.
Zelluna ASA Quarterly report: Q1 2026
Zelluna ASA has published its Q1 2026 quarterly earnings report on May 7, 2026.
Zelluna ASA Slides: Q1 2026
Zelluna ASA has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 7, 2026.
Zelluna ASA Transcript: Capital Markets Update 2026
A novel off-the-shelf cell therapy platform is advancing to clinical trials for solid tumors, targeting MAGE-A4 with a dual TCR-NK mechanism. The phase I study will focus on safety and proof of mechanism, with initial data expected from mid-2026.
Zelluna ASA Slides: FY 2026
Zelluna ASA has posted slides in relation to its FY 2026 quarterly earnings report, which was published on April 14, 2026.
Q4 2025 Zelluna ASA Earnings Presentation Transcript
Q4 2025 Zelluna ASA Earnings Presentation Transcript
Zelluna ASA Earnings Call Transcript: Q4 2025
Raised NOK 58 million, extending cash runway into Q1 2027, and advanced ZIMA-401 to first-in-human trials with strong preclinical data. Discontinued non-core programs to focus on scalable TCR-NK platform, with initial clinical data expected mid-2026.
Zelluna ASA Annual report: Q4 2025
Zelluna ASA has published its Q4 2025 annual report on February 12, 2026.
Zelluna ASA Quarterly report: Q4 2025
Zelluna ASA has published its Q4 2025 quarterly earnings report on February 12, 2026.
Zelluna ASA Slides: Q4 2025
Zelluna ASA has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on February 12, 2026.
Zelluna ASA Earnings Call Transcript: Q3 2025
Raised NOK 58 million, extending funding into Q1 2027, and advanced the lead TCR-NK program toward clinical trials with first patient data expected mid-2026. Positive regulatory feedback and pipeline expansion position the company for potential value inflection.
Zelluna ASA Quarterly report: Q3 2025
Zelluna ASA has published its Q3 2025 quarterly earnings report on November 4, 2025.
Zelluna ASA Slides: Q3 2025
Zelluna ASA has posted slides in relation to its Q3 2025 quarterly earnings report, which was published on November 4, 2025.
Zelluna ASA Earnings Call Transcript: Q2 2025
On track for IND/CTA filing for lead program ZI-MA4-1 in H2 2025, with first human data expected H1 2026. Cash position of NOK 76 million provides runway into Q2 2026, as R&D and transaction costs impact short-term results. Strong sector momentum for off-the-shelf cell therapies.
Zelluna ASA Quarterly report: Q2 2025
Zelluna ASA has published its Q2 2025 quarterly earnings report on August 20, 2025.
Zelluna ASA Slides: Q2 2025
Zelluna ASA has posted slides in relation to its Q2 2025 quarterly earnings report, which was published on August 20, 2025.